Advertisement

Topics

Pharmerica Corporation (PMC) Stock Rating Upgraded by Zacks Investment Research

08:46 EDT 29 Sep 2017 | Topix

The firm presently has a $33.00 target price on the stock. Zacks Investment Research 's price objective indicates a potential upside of 12.82% from the stock's current price.

Original Article: Pharmerica Corporation (PMC) Stock Rating Upgraded by Zacks Investment Research

NEXT ARTICLE

More From BioPortfolio on "Pharmerica Corporation (PMC) Stock Rating Upgraded by Zacks Investment Research"

Advertisement
Quick Search
Advertisement
Advertisement